Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1

Hee Jeong Cho, Hye Jeong Shin, In Kwon Han, Woon Won Jung, Young Bong Kim, Dong Geun Sul, Yu Kyoung Oh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Human papillomavirus type 16 L1 (HPV16 L1) has shown considerable promise as a parenteral vaccine for prevention of cervical cancers. Here, we report the possibility of oral vaccination for HPV16 L1 using Lactococcus lactis (L. lactis) as a live vector. L. lactis MG1363 was transformed with two types of HPV16 L1-encoding plasmids for intracellular expression or secretion. L. lactis transformed with HPV16 L1-encoding plasmids retained biochemical lactic acid production capability. The mucosal and systemic immune responses were affected by the cellular location of expressed HPV16 L1 proteins in L. lactis. Serum IgG responses were induced after oral immunizations of L. lactis secreting HPV16 L1. Vaginal IgA immune responses were observed following oral immunization with L. lactis expressing HPV16 L1 in an intracellular form, but not with L. lactis secreting HPV16 L1. Furthermore, induction of HPV16 L1-specific mucosal immune responses was affected by immunization frequency. Six immunizations over 5 weeks were required to induce vaginal immune responses. The levels of HPV16 L1-specific vaginal IgA were maintained until 12 weeks after the first vaccination. These results suggest the feasibility of L. lactis as an oral vaccine vehicle of HPV16 L1 and demonstrate the importance of cellular loci of expressed antigen for induction of vaginal and systemic immune responses.

Original languageEnglish
Pages (from-to)8049-8057
Number of pages9
JournalVaccine
Volume25
Issue number47
DOIs
Publication statusPublished - 2007 Nov 19

Fingerprint

oral vaccination
Mucosal Immunity
Lactococcus lactis
Human papillomavirus 16
Papillomaviridae
Immunization
immune response
mice
Immunoglobulin A
Vaccination
Plasmids
Vaccines
plasmids
immunization
vaccines
mucosal immunity
uterine cervical neoplasms
Uterine Cervical Neoplasms
lactic acid
Lactic Acid

Keywords

  • Human papillomavirus
  • Lactococcus lactis
  • Mucosal immune response
  • Oral immunization
  • Oral vaccine vehicle

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. / Cho, Hee Jeong; Shin, Hye Jeong; Han, In Kwon; Jung, Woon Won; Kim, Young Bong; Sul, Dong Geun; Oh, Yu Kyoung.

In: Vaccine, Vol. 25, No. 47, 19.11.2007, p. 8049-8057.

Research output: Contribution to journalArticle

Cho, Hee Jeong ; Shin, Hye Jeong ; Han, In Kwon ; Jung, Woon Won ; Kim, Young Bong ; Sul, Dong Geun ; Oh, Yu Kyoung. / Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. In: Vaccine. 2007 ; Vol. 25, No. 47. pp. 8049-8057.
@article{855e71f59add498e88a533152a6115ad,
title = "Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1",
abstract = "Human papillomavirus type 16 L1 (HPV16 L1) has shown considerable promise as a parenteral vaccine for prevention of cervical cancers. Here, we report the possibility of oral vaccination for HPV16 L1 using Lactococcus lactis (L. lactis) as a live vector. L. lactis MG1363 was transformed with two types of HPV16 L1-encoding plasmids for intracellular expression or secretion. L. lactis transformed with HPV16 L1-encoding plasmids retained biochemical lactic acid production capability. The mucosal and systemic immune responses were affected by the cellular location of expressed HPV16 L1 proteins in L. lactis. Serum IgG responses were induced after oral immunizations of L. lactis secreting HPV16 L1. Vaginal IgA immune responses were observed following oral immunization with L. lactis expressing HPV16 L1 in an intracellular form, but not with L. lactis secreting HPV16 L1. Furthermore, induction of HPV16 L1-specific mucosal immune responses was affected by immunization frequency. Six immunizations over 5 weeks were required to induce vaginal immune responses. The levels of HPV16 L1-specific vaginal IgA were maintained until 12 weeks after the first vaccination. These results suggest the feasibility of L. lactis as an oral vaccine vehicle of HPV16 L1 and demonstrate the importance of cellular loci of expressed antigen for induction of vaginal and systemic immune responses.",
keywords = "Human papillomavirus, Lactococcus lactis, Mucosal immune response, Oral immunization, Oral vaccine vehicle",
author = "Cho, {Hee Jeong} and Shin, {Hye Jeong} and Han, {In Kwon} and Jung, {Woon Won} and Kim, {Young Bong} and Sul, {Dong Geun} and Oh, {Yu Kyoung}",
year = "2007",
month = "11",
day = "19",
doi = "10.1016/j.vaccine.2007.09.024",
language = "English",
volume = "25",
pages = "8049--8057",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "47",

}

TY - JOUR

T1 - Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1

AU - Cho, Hee Jeong

AU - Shin, Hye Jeong

AU - Han, In Kwon

AU - Jung, Woon Won

AU - Kim, Young Bong

AU - Sul, Dong Geun

AU - Oh, Yu Kyoung

PY - 2007/11/19

Y1 - 2007/11/19

N2 - Human papillomavirus type 16 L1 (HPV16 L1) has shown considerable promise as a parenteral vaccine for prevention of cervical cancers. Here, we report the possibility of oral vaccination for HPV16 L1 using Lactococcus lactis (L. lactis) as a live vector. L. lactis MG1363 was transformed with two types of HPV16 L1-encoding plasmids for intracellular expression or secretion. L. lactis transformed with HPV16 L1-encoding plasmids retained biochemical lactic acid production capability. The mucosal and systemic immune responses were affected by the cellular location of expressed HPV16 L1 proteins in L. lactis. Serum IgG responses were induced after oral immunizations of L. lactis secreting HPV16 L1. Vaginal IgA immune responses were observed following oral immunization with L. lactis expressing HPV16 L1 in an intracellular form, but not with L. lactis secreting HPV16 L1. Furthermore, induction of HPV16 L1-specific mucosal immune responses was affected by immunization frequency. Six immunizations over 5 weeks were required to induce vaginal immune responses. The levels of HPV16 L1-specific vaginal IgA were maintained until 12 weeks after the first vaccination. These results suggest the feasibility of L. lactis as an oral vaccine vehicle of HPV16 L1 and demonstrate the importance of cellular loci of expressed antigen for induction of vaginal and systemic immune responses.

AB - Human papillomavirus type 16 L1 (HPV16 L1) has shown considerable promise as a parenteral vaccine for prevention of cervical cancers. Here, we report the possibility of oral vaccination for HPV16 L1 using Lactococcus lactis (L. lactis) as a live vector. L. lactis MG1363 was transformed with two types of HPV16 L1-encoding plasmids for intracellular expression or secretion. L. lactis transformed with HPV16 L1-encoding plasmids retained biochemical lactic acid production capability. The mucosal and systemic immune responses were affected by the cellular location of expressed HPV16 L1 proteins in L. lactis. Serum IgG responses were induced after oral immunizations of L. lactis secreting HPV16 L1. Vaginal IgA immune responses were observed following oral immunization with L. lactis expressing HPV16 L1 in an intracellular form, but not with L. lactis secreting HPV16 L1. Furthermore, induction of HPV16 L1-specific mucosal immune responses was affected by immunization frequency. Six immunizations over 5 weeks were required to induce vaginal immune responses. The levels of HPV16 L1-specific vaginal IgA were maintained until 12 weeks after the first vaccination. These results suggest the feasibility of L. lactis as an oral vaccine vehicle of HPV16 L1 and demonstrate the importance of cellular loci of expressed antigen for induction of vaginal and systemic immune responses.

KW - Human papillomavirus

KW - Lactococcus lactis

KW - Mucosal immune response

KW - Oral immunization

KW - Oral vaccine vehicle

UR - http://www.scopus.com/inward/record.url?scp=35448935267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448935267&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.09.024

DO - 10.1016/j.vaccine.2007.09.024

M3 - Article

VL - 25

SP - 8049

EP - 8057

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 47

ER -